Advertisement

Topics

Janssen Reports Top-Line Phase 3 Results for Tremfya in Adults with Active Psoriatic Arthritis

10:33 EDT 14 Jun 2019 | Speciality Pharma Journal

HORSHAM, Pa.–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced top-line results from the Phase 3 DISCOVER 1 and 2 studies, which evaluated the efficacy and safety of guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis (PsA). Both studies met their primary endpoints of American College of …

Original Article: Janssen Reports Top-Line Phase 3 Results for Tremfya in Adults with Active Psoriatic Arthritis

NEXT ARTICLE

More From BioPortfolio on "Janssen Reports Top-Line Phase 3 Results for Tremfya in Adults with Active Psoriatic Arthritis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...